159837 生物科技
未开盘 12-24 09:30:00
资讯
新帖
简况
盈康一生将打造生物科技旗舰，整合旗下海尔生物和上海莱士
证券之星 · 12-23 07:57
盈康一生将打造生物科技旗舰，整合旗下海尔生物和上海莱士
金十数据整理：每日港股市场要闻速递（12月20日 周五）
美港电讯 · 12-20
金十数据整理：每日港股市场要闻速递（12月20日 周五）
药明康德(603259.SH)拟认购海外私募基金份额 聚焦欧洲生物科技企业等
智通财经 · 12-19
药明康德(603259.SH)拟认购海外私募基金份额 聚焦欧洲生物科技企业等
会同天心生物科技有限公司原料装卸项目（第二次）招标公告
湖南新五丰 · 12-17
会同天心生物科技有限公司原料装卸项目（第二次）招标公告
宝积资本(08168)与婷创(郯城)生物科技订立谅解备忘录
智通财经 · 12-16
宝积资本(08168)与婷创(郯城)生物科技订立谅解备忘录
丸美股份更名丸美生物 聚焦生物科技引领抗衰未来
证券之星 · 12-12
丸美股份更名丸美生物 聚焦生物科技引领抗衰未来
每日全球并购：新华制药收购挪亚圣诺太仓生物科技股权 迪桑特增持宁波乐卡克服饰至75%股权（12/11）
晨哨并购 · 12-11
每日全球并购：新华制药收购挪亚圣诺太仓生物科技股权 迪桑特增持宁波乐卡克服饰至75%股权（12/11）
中源协和：目前，公司持有深圳市北科生物科技有限公司11.05%股权，未曾收到其IPO工作的通知
每日经济新闻 · 12-11
中源协和：目前，公司持有深圳市北科生物科技有限公司11.05%股权，未曾收到其IPO工作的通知
翰宇药业旗下公司与龙麻科技签订战略合作协议
美港电讯 · 12-11
翰宇药业旗下公司与龙麻科技签订战略合作协议
每日全球并购：新华制药收购挪亚圣诺太仓生物科技股权 迪桑特增持宁波乐卡克服饰至75%股权（12/10）
晨哨并购 · 12-10
每日全球并购：新华制药收购挪亚圣诺太仓生物科技股权 迪桑特增持宁波乐卡克服饰至75%股权（12/10）
山东新华制药股份(00719)拟收购挪亚圣诺(太仓)生物科技不超过75%的股权以完善鱼油产业链条
智通财经 · 12-09
山东新华制药股份(00719)拟收购挪亚圣诺(太仓)生物科技不超过75%的股权以完善鱼油产业链条
富国银行看好这只生物科技股，牛市情况下将上涨75%
金融界 · 12-04
富国银行看好这只生物科技股，牛市情况下将上涨75%
方舟健客(06086.HK)获纳入恒生香港上市生物科技指数
阿斯达克财经 · 12-03
方舟健客(06086.HK)获纳入恒生香港上市生物科技指数
方舟健客(06086)纳入恒生香港上市生物科技指数成份股
智通财经 · 12-03
方舟健客(06086)纳入恒生香港上市生物科技指数成份股
摩根大通：2025是生物科技的反弹之年，这几支值得提前布局
金融界 · 12-03
摩根大通：2025是生物科技的反弹之年，这几支值得提前布局
眼科生物科技公司“拨康视云”，递交招股书，拟香港上市，瑞银、建银、华泰联席保荐
市场资讯 · 12-03
眼科生物科技公司“拨康视云”，递交招股书，拟香港上市，瑞银、建银、华泰联席保荐
平安银行落地股票回购贷款 已与超200家上市公司建立合作意向
美港电讯 · 12-02
平安银行落地股票回购贷款 已与超200家上市公司建立合作意向
联康生物科技(00690.HK)重组胶原蛋白二类医疗器械获批 肌颜态医疗美容产品上市
阿斯达克财经 · 12-02
联康生物科技(00690.HK)重组胶原蛋白二类医疗器械获批 肌颜态医疗美容产品上市
港交所文件显示，轩竹生物科技提交了上市前文件，中金公司为其独家保荐人。
美港电讯 · 11-25
港交所文件显示，轩竹生物科技提交了上市前文件，中金公司为其独家保荐人。
港股午评：恒生指数半日跌0.12% 汽车、煤炭、内银股跌幅居前
美港电讯 · 11-20
港股午评：恒生指数半日跌0.12% 汽车、煤炭、内银股跌幅居前
暂无数据
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159837","market":"SZ","secType":"STK","nameCN":"生物科技","latestPrice":0.451,"timestamp":1735002045000,"preClose":0.451,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","marketStatusCode":0,"change":0,"latestTime":"12-24 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"adjPreClose":0.451,"symbolType":"fund","openAndCloseTimeList":[[1735003800000,1735011000000],[1735016400000,1735023600000]],"highLimit":0.496,"lowLimit":0.406,"ibTradeSell":false,"ibTradeBuySell":true,"pbRate":0,"marketValue":0,"floatMarketCap":0,"changeRate":0,"turnoverRate":0,"status":2,"discountRate":"0.00%","netWorth":"0.000"},"requestUrl":"/m/hq/s/159837/tweets","defaultTab":"tweets","newsList":[{"id":"2493275057","title":"盈康一生将打造生物科技旗舰，整合旗下海尔生物和上海莱士","url":"https://stock-news.laohu8.com/highlight/detail?id=2493275057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493275057?lang=zh_cn&edition=full","pubTime":"2024-12-23 07:57","pubTimestamp":1734911825,"startTime":"0","endTime":"0","summary":"12月22日晚间，青岛海尔生物医疗股份有限公司发布关于筹划重大资产重组的停牌公告。海尔生物拟于2024年12月23日开市起开始停牌，预计停牌时间不超过10个交易日。公开资料显示，海尔生物与上海莱士均为海尔集团大健康产业“盈康一生”旗下上市公司。业内人士解读，海尔生物与上海莱士不仅归属于同一实控人，在产业上也有诸多协同点，包括战略规划、产品研发、市场网络、成本管理、海外拓展等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024122300001183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","159837","BK0028","BK0188","002252","BK0251","LU2488822045.USD","688139","BK0046"],"gpt_icon":0},{"id":"2492543211","title":"金十数据整理：每日港股市场要闻速递（12月20日 周五）","url":"https://stock-news.laohu8.com/highlight/detail?id=2492543211","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492543211?lang=zh_cn&edition=full","pubTime":"2024-12-20 08:59","pubTimestamp":1734656375,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["603259","07226","159837","EURmain","LU0149721374.USD","ETH","01398","LU1688375341.USD","TNmain","LU0128522744.USD","601398","02598","LU1196710864.SGD","LU0029875118.USD","00999","FXE","LU2362541513.USD","02359","02005","HTCD.SI","EUO","IE00BZ1G4Q59.USD","LU2237443895.HKD","00700","ZBmain","02511","UBmain","600036","80700","LU2045819591.USD","MEURmain","002352","03143","LU0106252389.USD","03968","HSCEI","SG9999000327.SGD","SG9999001903.USD","ZFmain","ZNmain","02696","ZTmain","06936","YANG","LU0882574139.USD","LU0163747925.USD","LU1720050803.USD","TCEHY","HSTECH"],"gpt_icon":0},{"id":"2492147858","title":"药明康德(603259.SH)拟认购海外私募基金份额 聚焦欧洲生物科技企业等","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492147858?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:08","pubTimestamp":1734602883,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德 发布公告，公司全资子企业WuXi Pharma Tech Healthcare Fund I L.P.拟以有限合伙人身份认购SOFINNOVA BIOVELOCITA II S.L.P.基金份额，认购金额为1000万欧元;同时，WuXi Fund I拟以有限合伙人身份认购SOFINNOVA CROSSOVER II S.L.P.基金份额，认购金额为1000万欧元。据悉，SBV II重点聚焦于欧洲地区生物科技企业创建及种子投资活动，基金计划完成10-15个早期技术转化及种子项目投资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU1997245177.USD","BK1141","LU0456842615.SGD","LU1046422090.SGD","LU0320764599.SGD","BK0216","159837","603259","LU0708995583.HKD","LU2242644610.SGD","LU2045819591.USD","BK1576","LU2488822045.USD","LU1997245094.SGD","LU0052750758.USD","LU2125910500.SGD","02359"],"gpt_icon":0},{"id":"2492937315","title":"会同天心生物科技有限公司原料装卸项目（第二次）招标公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2492937315","media":"湖南新五丰","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492937315?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:09","pubTimestamp":1734430140,"startTime":"0","endTime":"0","summary":"本招标项目为会同天心生物科技有限公司原料装卸项目（第二次），资金来源为自筹，招标人为会同天心生物科技有限公司。项目已具备招标条件，现对该项目委托由湖南新五丰股份有限公司自行组织公开招标。2）装卸地点：会同县连山工业园区会同天心生物科技有限公司。以上应有的资料缺少一项或出现一项错误均不予领取招标文件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-17/doc-inczukxp1556071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837"],"gpt_icon":0},{"id":"2491962661","title":"宝积资本(08168)与婷创(郯城)生物科技订立谅解备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2491962661","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491962661?lang=zh_cn&edition=full","pubTime":"2024-12-16 19:30","pubTimestamp":1734348618,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝积资本(08168)于2024年12月16日(交易时段后)，公司与婷创(郯城)生物科技订立谅解备忘录，据此，订约方同意真诚磋商以就可能合作订立正式协议，合作方式包括但不限于业务合作及产品推广、策略性投资、成立合营公司及╱或提供融资。据悉，婷创(郯城)生物科技主要于中国从事研发、生产及销售益生菌产品。董事认为，可能合作为集团提供探索其收入来源多元化的可能性或向集团提供额外收入的战略机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","08168","159837"],"gpt_icon":0},{"id":"2490877846","title":"丸美股份更名丸美生物 聚焦生物科技引领抗衰未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2490877846","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490877846?lang=zh_cn&edition=full","pubTime":"2024-12-12 09:29","pubTimestamp":1733966981,"startTime":"0","endTime":"0","summary":"丸美股份公告，正式更名为丸美生物(603983.SH)，此次更名已获得上交所批准并公告完成。作为抗衰领域的领军企业，丸美生物在皮肤科学和生物可持续研究方面深耕超过20年，积累了深厚的技术实力和丰富的研发经验。公司已获得超过300项授权专利，尤其在重组胶原蛋白领域，获得授权专利超过30项，具备强大的自研、自产、自迭代能力，并于2024年8月获批成为首个全国重组功能蛋白技术研究中心的依托单位。公司业绩已连续多个季度保持近30%增长。丸美生物的成功转型和更名，体现了公司对生物科技的坚定投入和对未来发展的清晰规划。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121200008365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159837","BK0229","603983"],"gpt_icon":0},{"id":"2490852974","title":"每日全球并购：新华制药收购挪亚圣诺太仓生物科技股权 迪桑特增持宁波乐卡克服饰至75%股权（12/11）","url":"https://stock-news.laohu8.com/highlight/detail?id=2490852974","media":"晨哨并购","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490852974?lang=zh_cn&edition=full","pubTime":"2024-12-11 21:15","pubTimestamp":1733922900,"startTime":"0","endTime":"0","summary":"尽管近期经营挑战导致产量指引下调和股价下跌，Paladin Energy已采取措施改善运营，并预计在2025年实现更高的生产运作率。此次收购旨在通过1E的平台，为TeamViewer的客户提供智能解决方案，以预防和解决技术问题，从而进入智能端点管理的新时代。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-11/doc-inczcari3772903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000756","159837","BK0164","BK0239"],"gpt_icon":0},{"id":"2490333108","title":"中源协和：目前，公司持有深圳市北科生物科技有限公司11.05%股权，未曾收到其IPO工作的通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2490333108","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490333108?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:33","pubTimestamp":1733905980,"startTime":"0","endTime":"0","summary":"贵公司是否参股干细胞研发企业北科生物，持股比例是多少，北科生物近期有否lPO打算？中源协和12月10日在投资者互动平台表示，公司的参股公司北京三有利和泽与北京首都医科大学共同研发的“人牙髓间充质干细胞注射液”已进入Ⅱ期临床试验，正处于患者入组阶段，其已将一切人力、物力、财力用于该项目科研工作，公司也会努力推动其研发工作。目前，公司持有深圳市北科生物科技有限公司11.05%股权，未曾收到其IPO工作的通知。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-12-11/doc-inczarzp3940583.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-12-11/doc-inczarzp3940583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600645","BK0188","BK0216","159837","BK0042","BK0239","BK0046"],"gpt_icon":0},{"id":"2490007896","title":"翰宇药业旗下公司与龙麻科技签订战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2490007896","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490007896?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:00","pubTimestamp":1733893254,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","300199","BK0077","BK0188","BK0070","159837","BK0028","159891"],"gpt_icon":0},{"id":"2490018948","title":"每日全球并购：新华制药收购挪亚圣诺太仓生物科技股权 迪桑特增持宁波乐卡克服饰至75%股权（12/10）","url":"https://stock-news.laohu8.com/highlight/detail?id=2490018948","media":"晨哨并购","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490018948?lang=zh_cn&edition=full","pubTime":"2024-12-10 20:47","pubTimestamp":1733834820,"startTime":"0","endTime":"0","summary":"迪桑特此前已持有宁波乐卡克40%的股份，此次将以35亿日元的价格增持至75%，而伊藤忠商事旗下子公司将持有剩余的25%股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-10/doc-incyytkm4815489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000756","BK0239","159837","BK0164"],"gpt_icon":0},{"id":"2490172879","title":"山东新华制药股份(00719)拟收购挪亚圣诺(太仓)生物科技不超过75%的股权以完善鱼油产业链条","url":"https://stock-news.laohu8.com/highlight/detail?id=2490172879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490172879?lang=zh_cn&edition=full","pubTime":"2024-12-09 19:30","pubTimestamp":1733743837,"startTime":"0","endTime":"0","summary":"随着国民健康需求的快速增长，鱼油产品的多元化市场需求仍保持较高增速，为尽快完善鱼油产业链条，公司拟通过收购目标公司部分股权来加快在鱼油产业方面的布局。目标公司与公司鱼油产业具有高度互补性和协同性，建议交易符合公司在大健康板块的战略规划与布局，有利于公司实现产业链延伸。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","159837","BK1515","00719"],"gpt_icon":0},{"id":"2488181963","title":"富国银行看好这只生物科技股，牛市情况下将上涨75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488181963","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488181963?lang=zh_cn&edition=full","pubTime":"2024-12-04 10:57","pubTimestamp":1733281027,"startTime":"0","endTime":"0","summary":"富国银行认为，Kymera Therapeutics成功的一款实验性治疗药物可能为该公司股票带来更多上涨空间。今年以来，该股表现已显著跑赢大盘，累计上涨近90%。预计该药物的I期试验数据将在2025年上半年公布。他预测数据可能显示出“良好”的安全性特征，并认为牛市情况下股价可能上涨75%。目前，Kymera的平均目标价为57.88美元，较当前股价有超过20%的上涨空间。受评级上调推动，该公司股价在周一交易时段上涨逾2%。","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2024/12/weixin/one_20241204105722849.png","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2024/12/weixin/one_20241204105722849.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/04105745989379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0251142724.SGD","LU0149725797.USD","LU1363072403.SGD","LU2236285917.USD","LU2461242641.AUD","LU0208291251.USD","LU0052756011.USD","LU0130517989.USD","LU1201861249.SGD","LU0310800965.SGD","WFC","LU1280957306.USD","LU0477156953.USD","BK4207","IE0002270589.USD","LU0417517546.SGD","LU1668664300.SGD","BK4559","LU0256863811.USD","LU2361044865.SGD","LU0320765489.SGD","BK4504","BK4585","LU0162691827.USD","LU0175139822.USD","LU0640476718.USD","LU0106831901.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0070302665.USD","LU2361044949.HKD","LU1814569148.SGD","159837","LU1074936037.SGD","BK4501","LU1035773651.USD","LU0289960550.SGD","LU1267930227.SGD","LU0971096721.USD","LU2361045086.USD","LU1791807156.HKD","LU0130102774.USD","IE00B7SZLL34.SGD","LU0683600562.USD","LU0787776722.HKD","BK4588","LU0072461881.USD","LU1069347547.HKD","LU0048573561.USD","LU0128525689.USD"],"gpt_icon":0},{"id":"2488942284","title":"方舟健客(06086.HK)获纳入恒生香港上市生物科技指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2488942284","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488942284?lang=zh_cn&edition=full","pubTime":"2024-12-03 23:50","pubTimestamp":1733241000,"startTime":"0","endTime":"0","summary":"方舟健客(06086.HK) 公布，公司股份已获选定纳入恒生香港上市生物科技指数，自12月9日起生效。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240703113906445_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240703113906445_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401504/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06086","BK1247","159837"],"gpt_icon":0},{"id":"2488994062","title":"方舟健客(06086)纳入恒生香港上市生物科技指数成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2488994062","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488994062?lang=zh_cn&edition=full","pubTime":"2024-12-03 18:15","pubTimestamp":1733220946,"startTime":"0","endTime":"0","summary":"智通财经APP讯，方舟健客(06086)发布公告，公司股份已获选定纳入恒生香港上市生物科技指数(“恒生香港上市生物科技指数”)，自2024年12月9日起生效。恒生香港上市生物科技指数旨在反映于香港上市的生物科技公司的整体表现。董事会认为，股份纳入恒生香港上市生物科技指数成份股可提升公司于更为广泛的投资者中的形象，且亦可为我们的客户、合作伙伴及投资者创造机会以参与公司的创新互联网保健解决方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1247","06086","159837"],"gpt_icon":0},{"id":"2488826965","title":"摩根大通：2025是生物科技的反弹之年，这几支值得提前布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2488826965","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488826965?lang=zh_cn&edition=full","pubTime":"2024-12-03 14:14","pubTimestamp":1733206449,"startTime":"0","endTime":"0","summary":"2024年对于生物技术股来说是另一个“具有挑战性”的年份，但根据JPMorgan的分析，某些公司在未来几个月可能迎来上涨的机会。相比之下，标准普尔500指数今年的涨幅超过了四倍，接近26%。总的来说，JPMorgan的分析师们认为，生物技术领域的创新仍将推动一些优质公司在2025年迎来新的增长机会，尽管面临宏观经济和政策环境的不确定性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/03141445946699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0256863811.USD","IE00BWXC8680.SGD","LU2552382058.USD","159837","LU1894683264.USD","IE00B3S45H60.SGD","LU0211328371.USD","LU1267930490.SGD","IE00B1BXHZ80.USD","BK4550","LU2264538146.SGD","SG9999002232.USD","BK4533","IE0034235188.USD","LU0787776722.HKD","BK4207","LU1064131342.USD","IE0034235295.USD","IE00BDRTCR15.USD","BK4504","LU0251132253.USD","LU0323591593.USD","LU1720051017.SGD","LU2023250843.SGD","LU1974910355.USD","IE00BLSP4452.SGD","LU1670627923.USD","LU1244550577.SGD","LU1670628061.USD","IE0034235303.USD","LU1119994496.HKD","LU0267386448.USD","LU1914381329.SGD","LU0976567544.SGD","BK4585","IE00BBT3K403.USD","JPM","LU2552382132.HKD","LU0106831901.USD","LU0203347892.USD","LU1032466523.USD","LU0417517546.SGD","LU1244550221.USD","LU1261432733.SGD","LU1244550494.USD","LU0211326839.USD","LU2106854487.HKD","LU0203345920.USD","IE00B1XK9C88.USD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2488907959","title":"眼科生物科技公司“拨康视云”，递交招股书，拟香港上市，瑞银、建银、华泰联席保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2488907959","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488907959?lang=zh_cn&edition=full","pubTime":"2024-12-03 13:14","pubTimestamp":1733202840,"startTime":"0","endTime":"0","summary":" 2024年12月2日，Cloudbreak Pharma Inc．向港交所递交招股书，拟香港主板挂牌上市。这是继其于2023年11月30日、2024年5月31日递表失效后的再一次申请。 拨康视云，成立于2015年，作为一家以创新驱动的临床阶段眼科生物科技公司，致力于开发新型及差异化疗法。 拨康视云已建立一个由八种候选药物组成的广泛而创新的管线，覆盖眼睛前部及后部的主要疾病，其中有四款处于临床阶段的候选药物、四款处于临床前阶段的候选药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2024-12-03/doc-incyeers8513834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837"],"gpt_icon":0},{"id":"2488621603","title":"平安银行落地股票回购贷款 已与超200家上市公司建立合作意向","url":"https://stock-news.laohu8.com/highlight/detail?id=2488621603","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488621603?lang=zh_cn&edition=full","pubTime":"2024-12-02 17:55","pubTimestamp":1733133301,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["000808.SH","LU0501845795.SGD","000001","LU1226287529.USD","LU0880133367.SGD","LU0072913022.USD","BK0188","LU1655091616.SGD","BK0187","LU0067412154.USD","LU1807302812.USD","159837","163118","BK0012","BK0028","BK0183","IE00B0JY6N72.USD","LU1993786604.SGD","BK0201","159582","BK0278"],"gpt_icon":0},{"id":"2488629955","title":"联康生物科技(00690.HK)重组胶原蛋白二类医疗器械获批 肌颜态医疗美容产品上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2488629955","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488629955?lang=zh_cn&edition=full","pubTime":"2024-12-02 17:22","pubTimestamp":1733131320,"startTime":"0","endTime":"0","summary":"联康生物科技集团(00690.HK) 公布两项重要里程碑。集团与重庆民济医疗器械有限公司的战略合作产品-医用重组胶原蛋白敷料，已成功获批二类医疗器械注册证。另一个扩充产品组合的重要里程碑，是基于集团的专利原料-Skbrella TM FN自主研发的医疗美容品牌-“肌颜态”的正式上市。肌颜态旨在提供安全有效的皮肤护理解决方案，以修复和改善皮肤质量，尤其是针对受损或敏感肌的患者。同时，集团正在推进基于纤连蛋白成分的医疗器械的研发。(sl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200210151623580_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200210151623580_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401156/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09996","BK1583","159837","BK1100","00690","159883","BK1161","BK1222","BK1574","09997"],"gpt_icon":0},{"id":"2486035040","title":"港交所文件显示，轩竹生物科技提交了上市前文件，中金公司为其独家保荐人。","url":"https://stock-news.laohu8.com/highlight/detail?id=2486035040","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486035040?lang=zh_cn&edition=full","pubTime":"2024-11-25 23:25","pubTimestamp":1732548350,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1516","BK0276","159837","BK1147","SG9999002828.SGD","03908","BK1564","601995","BK1501"],"gpt_icon":0},{"id":"2484132302","title":"港股午评：恒生指数半日跌0.12% 汽车、煤炭、内银股跌幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2484132302","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484132302?lang=zh_cn&edition=full","pubTime":"2024-11-20 12:07","pubTimestamp":1732075635,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["81024","SG9999001093.SGD","MHImain","80700","LU0049853897.USD","00700","02833","GWLLY","LU1044875133.USD","BIDU","161032","BK1095","TTTN","01024","HSTECH","09888","LU0348814723.USD","HHImain","03086","02333","TCEHY","82333","HSI","YANG","601633","BK1588","LU1282648689.USD","513600","LU1105468828.SGD","MCHmain","07226","89888","HTCD.SI","LU0880133367.SGD","159938","000488","09939","HSImain","159582","SGXZ90724238.SGD","159837","09618","01812","09866","JD","89618","SG9999002828.SGD","LU0359201885.HKD","HSCEI"],"gpt_icon":0}],"profile":{"ret":0,"stockEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0066},{"period":"3month","weight":0.1654},{"period":"6month","weight":0.0789},{"period":"1year","weight":-0.131},{"period":"ytd","weight":-0.1538}],"compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1705},{"period":"6month","weight":0.1274},{"period":"1year","weight":0.1497},{"period":"ytd","weight":0.1265}],"serverTime":1735002075814,"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,159837,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}